---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-006891"
form_type: "8-K"
ticker: "BIXT"
cik: "0001445815"
company_name: "BIOXYTRAN, INC"
filed_at: "2026-02-17T23:59:59+00:00"
generated_at: "2026-05-16T02:23:40.083455+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Bioxytran signs distribution deal with Khoury Medical for A-SUQAR supplement

## Summary
- Agreement with Khoury Medical to commercialize A-SUQAR, a chewable blood sugar supplement using Bioxytran's PHGG formulation.
- CEO David Platt says deal marks transition from development-stage to recurring commercial revenue while preserving IP ownership.
- Volume-based marketplace exclusivity possible if defined purchase thresholds are met, per agreement terms.
- Initial commercial shipments expected after completion of standard launch preparations; manufacturing by Bioxytran's OEM.
- Bioxytran retains full IP; deal applies only to non-pharmaceutical dietary products, preserving pharma/antiviral programs.

## SEC filing metadata
- accession: 0001493152-26-006891
- form_type: 8-K
- ticker: BIXT
- cik: 0001445815
- company_name: BIOXYTRAN, INC
- filed_at: 2026-02-17T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1445815/000149315226006891/0001493152-26-006891-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1445815/000149315226006891/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-006891
- JSON: https://secwatch.observer/filing/0001493152-26-006891.json
- Plain text: https://secwatch.observer/filing/0001493152-26-006891.txt

## Key facts
- Material Agreements
  BIOXYTRAN, INC entered into Distribution Agreement with Khoury Medical LTD (effective 2026-02-10).
  - Action: entry
  - Agreement: supply
  - Counterparty: Khoury Medical LTD
  - Effective: 2026-02-10
  source text: On February 10, 2026, Bioxytran entered into a commercial Distribution Agreement, attached hereto as Exhibit 10.90, with Khoury Medical LTD
  evidence_url: https://www.sec.gov/Archives/edgar/data/1445815/000149315226006891/0001493152-26-006891-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.